Special Issue

Antiviral Drug Development for the Treatment of Human Coronavirus

Message from the Guest Editors

Viral infections still represent one major threat to human health. The coronavirus disease (COVID-19) pandemic has already claimed the lives of more than three million people worldwide and had a huge impact on everyone's daily lifestyle. Chiefly, similar to other RNA viruses, high mutation rates will make SARS-Cov-2 so cunning as to evade the attack of antibodies. According to a recent study, more than 12,000 mutations in SARS-CoV-2 genomes have been identified. Therefore, developing antiviral agents against SARS-CoV-2 is still in high demand. In this Special Issue, we aim to collect a series of high-quality reviews and research papers on antiviral drug development against human coronavirus. The scope includes but is not limited to structure-activity relationship studies, drug screening, drug repurposing, diagnosis and mechanism of action. In addition, we know that most of the institutions do not have the facility to conduct the activity test for highly pathogenic viruses such as SARS-Cov-2, so research papers dealing with any human coronavirus are also welcomed, especially the ones reporting broad-spectrum antiviral activities.

Guest Editors

Prof. Dr. Xingyue Ji

Prof. Dr. Yuhuan Li

Prof. Dr. Jiangning Liu

Deadline for manuscript submissions

closed (31 December 2021)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/87237

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).